800 million yuan crossborder This time, Shengxiang Bio has set its sights directly on the field of biologics in the pharmaceutical field.
According to the announcement, Shengxiang Bio plans to acquire 100% of the equity of Zhongshan Weiming Haiji Biotechnology Co., Ltd. for RMB 807.5 million in cash.
Zhongshan Weiming Haiji Biopharmaceutical Co., Ltd. was establish in 2004 and is locat in the National
Health Base in Torch District, Zhongshan City. It is palestinian territories email list 100000 contact leads a genetic engineering biopharmaceutical company with independent intellectual property rights.
The company has been engag in the research, development and production of genetically recombinant
products and biological products. Its main products are human growth hormone (shortacting powder
injection, shortacting water injection). It also has an integrat production workshop and new drug
research and development center that meets national GMP standards and masters core process technologies.
The company independently produces all products from raw materials to final products
Covering the front and end of the industrial chain.
This acquisition has a certain premium. As of the valuation base date of May 31, 2024, the book value
of all shareholders’ equity of Zhongshan Haiji was RMB 259 million, the valuation was RMB 810
million, the appreciation was RMB 551 million, and the appreciation rate was 212.64%.
On the evening of January 12, Shengxiang Bio point out in a supplementary announcement that it had updat the financial data of Zhongshan Haiji.
Financial data shows that in 2023, Zhongshan Haiji we put a lot of things into play achiev operating income of 350 million yuan,
corresponding to a net profit of 48.2638 million yuan; from January to May 2024, the operating
income was 208 million yuan, corresponding to a net profit of 39.5782 million yuan; from January to
November 2024, the operating income was 408 million yuan, corresponding to a net profit of 105 million yuan.
The company also point out the risks
Since the equity acquisition is a merger of companies under liechtenstein number different control, after the completion of
this transaction, the target company will become a whollyown subsidiary of the company, and a certain amount of goodwill is expect to be generat in the company’s consolidat balance sheet 800 million yuan crossborder.